Read on
DAB, a spin-off from TU Delft, has raised € 2 million in Series A financing from and InnovationQuarter to accelerate the production of biobased chemicals and advanced fuels.
Editorial office / Delft

DAB develops innovative bioreactor technology that increases the productivity of fermentation processes and at the same time lowers operational costs. This allows its partners to produce cost-effective biobased products that can compete with fossil-based alternatives.

DAB Business advisor and senior business developer in industrial biotech Marc Lankveld said : ‘This investment in DAB by and Innovation Quarter is a strong encouragement for the Biotech industry in the Netherlands. It shows the willingness of financial investors to invest in new Biotechnology and thereby opening up all kind of new renewable solutions, like renewable jetfuels with a significant lower CO2 footprint.’

DAB will present its technology at several international events later this year. The company is already working with some high profile customers to implement pilot projects for new biobased compounds.